Search

Your search keyword '"SOGA, HIROKI"' showing total 6 results
Start Over Author "SOGA, HIROKI" Search Limiters Available in Library Collection
6 results on '"SOGA, HIROKI"'

1. Population‑based prostate‑specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan

Author

Kageyama, Susumu, primary, Okinaka, Yuki, additional, Nishizawa, Koji, additional, Yoshida, Toru, additional, Ishitoya, Satoshi, additional, Shichiri, Yasumasa, additional, Kim, Chul, additional, Iwata, Tsuyoshi, additional, Yokokawa, Ryusei, additional, Arai, Yutaka, additional, Nishikawa, Zenkai, additional, Soga, Hiroki, additional, Ushida, Hiroshi, additional, Sakano, Yuji, additional, Naya, Yoshio, additional, Wada, Akinori, additional, Nagasawa, Masayuki, additional, Yoshida, Tetsuya, additional, Narita, Mitsuhiro, additional, and Kawauchi, Akihiro, additional

Published
2022
Full Text
View/download PDF

2. Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer

Author

KAGEYAMA, SUSUMU, primary, MAEDA, KOKI, additional, KUBOTA, SHIGEHISA, additional, YOSHIDA, TETSUYA, additional, OSAFUNE, TAKASHI, additional, ARAI, YUTAKA, additional, SOGA, HIROKI, additional, NISHIKAWA, ZENKAI, additional, SAKANO, YUJI, additional, TAKIMOTO, KEITA, additional, KIM, CHUL JANG, additional, CHANO, TOKUHIRO, additional, and KAWAUCHI, AKIHIRO, additional

Published
2021
Full Text
View/download PDF

3. Pseudo-Kaposi's sarcoma of the hand associated with acquired iatrogenic arteriovenous fistula

Author

Nakanishi, Gen, Tachibana, Takao, Soga, Hiroki, Fujimoto, Noriki, and Tanaka, Toshihiro

Subjects
Kaposi's sarcoma -- Diagnosis -- Care and treatment -- Case studies -- Reports, Fistula, Arteriovenous -- Complications and side effects -- Case studies -- Reports, Health
Abstract

Byline: Gen. Nakanishi, Takao. Tachibana, Hiroki. Soga, Noriki. Fujimoto, Toshihiro. Tanaka Sir, Pseudo-Kaposi's sarcoma is considered an acquired benign reactive vascular proliferation that clinically resembles Kaposi's sarcoma. [sup][1] It can [...]

Published
2014

4. 前立腺肥大症患者の夜間頻尿と睡眠障害に対するナフトピジルの有用性について

Author

Iwaki, Hideaki, Narita, Mitsuhiro, Soga, Hiroki, Sakano, Yuji, Konishi, Taira, and Okada, Yusaku

Subjects
Benign prostatic hyperplasia, Naftopidil, Pittsburgh sleep quality index, Sleep disturbance, Nocturia, 494.9, urologic and male genital diseases
Abstract

Nocturnal urinary frequency is a predominant complaint among males presenting with benign prostatic hyperplasia (BPH), which markedly impacts quality of life (QOL) and often causes sleep disturbance. We studied the efficacy of naftopidil an alpha 1-adrenoreceptor antagonist used for treatment of BPH for improvement of nocturia and consequent sleep disturbance. Twenty-five patients diagnosed with BPH were administered daily oral doses of naftopidil (50 or 75 mg/day) for eight weeks. The symptoms were assessed quantitatively using the following criteria : International Prostate Symptoms Score (I-PSS), QOL index, frequency volume chart, and Pittsburgh Sleep Quality Index (PSQI). After treatment, the mean±SD of total I-PSS and nocturia decreased from 16.9±5.2 to 10.3±4.9 (p＜0.001) and 3.5±1.2 to 2.3±1.3 (p＜ 0.001), respectively. In addition, all categories of storage symptoms in I-PSS were also significantly improved. PSQI results were obtained in 21 of the 25 patients, and decreased from 6.4±4.2 to 5.3±3.5 (p＝0.026) (normal range : less than 5.5). This is the first report of a quantitative analysis of the effect of naftopidil on sleep quality in BPH patients. In conclusion, naftopidil appears to be an effective agent not only for nocturia and other urinary storage symptoms, but also for improving the quality of sleep.

Published
2010

5. This title is unavailable for guests, please login to see more information.

Author

Iwaki, Hideaki, Narita, Mitsuhiro, Soga, Hiroki, Sakano, Yuji, Konishi, Taira, Okada, Yusaku, Iwaki, Hideaki, Narita, Mitsuhiro, Soga, Hiroki, Sakano, Yuji, Konishi, Taira, and Okada, Yusaku

Abstract

Nocturnal urinary frequency is a predominant complaint among males presenting with benign prostatic hyperplasia (BPH), which markedly impacts quality of life (QOL) and often causes sleep disturbance. We studied the efficacy of naftopidil an alpha 1-adrenoreceptor antagonist used for treatment of BPH for improvement of nocturia and consequent sleep disturbance. Twenty-five patients diagnosed with BPH were administered daily oral doses of naftopidil (50 or 75 mg/day) for eight weeks. The symptoms were assessed quantitatively using the following criteria : International Prostate Symptoms Score (I-PSS), QOL index, frequency volume chart, and Pittsburgh Sleep Quality Index (PSQI). After treatment, the mean±SD of total I-PSS and nocturia decreased from 16.9±5.2 to 10.3±4.9 (p＜0.001) and 3.5±1.2 to 2.3±1.3 (p＜ 0.001), respectively. In addition, all categories of storage symptoms in I-PSS were also significantly improved. PSQI results were obtained in 21 of the 25 patients, and decreased from 6.4±4.2 to 5.3±3.5 (p＝0.026) (normal range : less than 5.5). This is the first report of a quantitative analysis of the effect of naftopidil on sleep quality in BPH patients. In conclusion, naftopidil appears to be an effective agent not only for nocturia and other urinary storage symptoms, but also for improving the quality of sleep.

Published
2010

6. Population‑based prostate‑specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan.

Author

Kageyama, Susumu, Okinaka, Yuki, Nishizawa, Koji, Yoshida, Toru, Ishitoya, Satoshi, Shichiri, Yasumasa, Kim, Chul Jang, Iwata, Tsuyoshi, Yokokawa, Ryusei, Arai, Yutaka, Nishikawa, Zenkai, Soga, Hiroki, Ushida, Hiroshi, Sakano, Yuji, Naya, Yoshio, Wada, Akinori, Nagasawa, Masayuki, Yoshida, Tetsuya, Narita, Mitsuhiro, and Kawauchi, Akihiro

Subjects
PROSTATE cancer, PROSTATE-specific antigen, EARLY detection of cancer, PROSTATE cancer patients, MEDICAL screening, MEDICAL records
Abstract

Prostate cancer is the most common genitourinary cancer in men. Population-based serum prostate-specific antigen (PSA) testing is used to screen men for the early detection of asymptomatic prostate cancer. The present study compared the features of patients with prostate cancer in Kusatsu City, the only municipality in Shiga Prefecture of Japan to implement organized PSA screening, with those in other municipalities. The target population for organized PSA screening by mail invitation was men ≥50 years. Patients were pathologically diagnosed via prostate biopsy because of elevated serum PSA. This multicenter observational study was subsequently conducted in 14 hospitals. The following information was extracted from patient records: age, reason for PSA testing, initial PSA level, Gleason score, clinical stage, and place of residence. Risk classification was defined as low, intermediate, high, and advanced. Each patient was stratified according to their city/town. A total of 984 patients diagnosed with prostate cancer in Shiga in 2012 and 2017 were analyzed, of which 955 (97%) were opportunistically tested, with the remaining 29 (3%) assessed by organized screening. In Kusatsu, 93 patients were diagnosed, of whom 26 (28%) were detected by organized screening. By contrast, only three of 891 patients (0.3%) were detected by organized screening in other municipalities. Of patients in Kusatsu, cases identified by opportunistic testing had a higher initial PSA value (P=0.010) than those identified by organized screening. However, patients detected through opportunistic testing in Kusatsu City were younger (P=0.034), had a lower PSA value (P=0.001), and improved risk classification (P<0.001) than those in other municipalities. It was concluded that more patients were diagnosed with early-stage cancer by organized PSA screening. Furthermore, population-based PSA screening in Kusatsu City may have indirectly affected early detection, even by opportunistic testing. [ABSTRACT FROM AUTHOR]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results